Trial · NCT07374549
SYS6002 vs PADCEV in Patients With Advanced Urothelial Carcinoma
NCT07374549, Phase 2, Not yet recruiting, CSPC Megalith Biopharmaceutical Co.,Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. SYS6002 vs PADCEV in Patients With Advanced Urothelial Carcinoma. Trials, record NCT07374549. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07374549
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- SYS6002 vs PADCEV in Patients With Advanced Urothelial Carcinoma
- NCT number
- NCT07374549
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 100 participants, estimated
- Lead sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
- Conditions
- Advanced Urothelial Carcinoma
- Interventions
- SYS6002, enfortumab vedotin
- First posted
- 2026-01-29
- Last updated
- 2026-01-29
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Occurrence and frequency of Adverse Event (AE) | Up to approximately 2 years | |
| Secondary | Incidence of treatment-related peripheral neuropathy and≥1-grade worsening in treatment-related peripheral neuropathy from baseline | Up to 2 years | |
| Secondary | Incidence of treatment-related hyperglycemia | Up to 2 years | |
| Secondary | Incidence of treatment-related cutaneous adverse reactions | Up to 2 years | |
| Secondary | Objective Response Rate (ORR) | Up to 2 years | Objective response rate is defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) per RECIST v.1.1. |
| Secondary | Duration of Response (DOR) | Up to 2 years | DOR is defined as the time from the date of the first confirmed objective response (CR or PR that is subsequently confirmed) to the date of the first documented disease progression (PD) per RECIST v1.1 or death from any cause, whichever occurs first |
| Secondary | Disease Control Rate (DCR) | :Up to 2 years | The percentage of participants who experience a best response of CR, PR or stable disease (SD). |
| Secondary | Progression Free Survival (PFS) | Up to 2 years | PFS is defined as the time from the date of randomization to the first documentation of PD as assessed by investigator per RECIST v.1.1, or death due to any cause, whichever occurs earlier. |
| Secondary | Overall Survival | Up to 2 years |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07374549
GET https://conductscience.org/api/trials/v1/NCT07374549/registered